PBM
KLRS

Propel Bio Management’s Kalaris Therapeutics KLRS Stock Holding History

Propel Bio Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
295,771
+253,718
+603% +$2.25M 1.08% 28
2025
Q4 		$355K Buy
+42,053
New +$269K 0.3% 20

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Propel Bio Management's KLRS Position: Q1 2026 in Review

Propel Bio Management increased its Kalaris Therapeutics (KLRS) stake by 603% in Q1 2026, buying an estimated $2.25M and bringing the position to 295,771 shares worth $1.72M. The position accounts for 1.08% of the portfolio, ranked #28.

Propel Bio Management first reported a position in KLRS in Q4 2025 and has held it in 2 quarters since. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Propel Bio Management held 295,771 shares of Kalaris Therapeutics worth $1.72M as of Q1 2026.
  • Propel Bio Management bought 253,718 Kalaris Therapeutics shares in Q1 2026, an estimated $2.25M.
  • Kalaris Therapeutics made up 1.08% of Propel Bio Management's portfolio in Q1 2026, its #28 holding.
  • Propel Bio Management first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.